Aurobindo Pharma USA has received approval from the U.S. Federal Trade Commission (FTC) to acquire Lannett Company LLC for $250 million. This strategic acquisition is expected to close by the end of June 2026. The deal will significantly expand Aurobindo USA’s product offerings in complex, non-opioid controlled substances and enhance its U.S.-based manufacturing capabilities, aligning with U.S. policy priorities.
FTC Approval Secured for Lannett Acquisition
Aurobindo Pharma USA, Inc., a wholly owned subsidiary of Aurobindo Pharma Limited, announced today that it has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC. The transaction, valued at $250 million on a cash-free, debt-free basis with normalized working capital, is anticipated to be completed before the end of June 2026.
Strategic Expansion and Synergies
Lannett, a Pennsylvania-based pharmaceutical company, specializes in the development and commercialization of a diverse portfolio of complex, non-opioid controlled substances. This acquisition is set to significantly broaden Aurobindo USA’s product range within this segment and integrate a U.S.-based manufacturing facility into its network. Lannett’s manufacturing site in Seymour, Indiana, possesses the capacity to produce approximately 4 billion doses annually, bolstering Aurobindo USA’s domestic manufacturing footprint and contributing to U.S. policy goals for supply chain resilience and increased domestic pharmaceutical production.
Financial and Operational Impact
The transaction is projected to be immediately accretive to Aurobindo Group’s earnings per share. Beyond immediate financial benefits, the acquisition is expected to yield substantial cost efficiencies, SG&A synergies, and operational integration advantages. It will also enrich the company’s portfolio with a differentiated pipeline of complex generics and controlled substances, supporting sustainable long-term growth.
“This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our U.S.-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances.”
– Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA
“We are delighted to be joining forces with Aurobindo. As one of the nation’s oldest generic pharmaceutical companies, Lannett has a proud history of helping patients access affordable medicines.”
– Tim Crew, Lannett Company’s Chief Executive Officer
About the Companies
Aurobindo Pharma USA, Inc. is a leading pharmaceutical company focused on the development, manufacturing, and commercialization of a broad range of generic and specialty pharmaceutical products.
Lannett Company LLC is a Pennsylvania-based pharmaceutical company specializing in the development and commercialization of complex generic pharmaceutical products, including non-opioid controlled substances.
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India, developing, manufacturing, and commercializing a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 150 countries. The company’s facilities are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, and South Africa MCC.
Source: BSE
